Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
August 14, 2024 16:01 ET
|
Celcuity Inc.
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast...
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
August 12, 2024 16:05 ET
|
ORIC Pharmaceuticals
Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and...
Orion Group Half-Year Financial Report January–June 2024
August 08, 2024 05:00 ET
|
Orion Oyj
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2024 8 AUGUST 2024 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2024 Net sales totalled EUR 636.7 (January–June 2023:...
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
August 07, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
July 17, 2024 01:30 ET
|
Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen...
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
July 16, 2024 16:59 ET
|
ORIC Pharmaceuticals
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial...
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
July 15, 2024 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Metastatic Prostate Cancer Markets, Pipeline Analysis, Epidemiology Forecast and Competition Data; 2018-2034
June 12, 2024 11:34 ET
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
Celcuity To Participate in Jefferies Global Healthcare Conference
June 03, 2024 16:01 ET
|
Celcuity Inc.
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
May 30, 2024 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...